Press Releases

Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise

...

Emergent BioSolutions to Host Conference Call on March 22, 2007 to Announce Fourth Quarter and Full Year 2006 Financial Results

...

Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference

...

Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax(R) Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile

...

Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures

...

FDA Grants Fast Track Designation to Emergent BioSolutions’ BioThrax(R) for Post-Exposure Prophylaxis against Anthrax Infection

...

Emergent BioSolutions to Present at BIO CEO & Investor Conference

...

Emergent BioSolutions Announces Expected 2006 Total Revenue of Approximately $150 Million

...

Emergent BioSolutions to Present at JPMorgan Healthcare Conference

...

National Institutes of Health to Sponsor Clinical Trial for Emergent BioSolutions’ Group B Streptococcus Vaccine Candidate

...

Emergent BioSolutions Applauds Passage and Signing of BARDA Legislation

...

Emergent BioSolutions Delivers over 3 Million Doses of BioThrax(R) to U.S. Department of Health and Human Services for Strategic National Stockpile

...